2 Healthcare Stocks Under $10 That Wall Street Predicts Will Double

NASDAQ: TTOO | T2 Biosystems, Inc. News, Ratings, and Charts

TTOO – The healthcare industry is growing, with significant investments in research and development and technological transformation. Given the industry tailwinds, Wall Street analysts expect healthcare stocks T2 Biosystems (TTOO) and OpGen (OPGN), which are currently trading at less than $10, to double in price soon. Come on, how can one not read on for details on this one?.

Unprecedented developments and therapeutic breakthroughs have been driving the healthcare industry’s growth, with MedTech and healthcare IT the fastest advancing segments. According to a recent survey, 92% of healthcare organizations believe they will achieve revenue growth in 2021, with one in five healthcare organizations considering a merger or acquisition this year. 

Healthcare companies are increasing their capital spending and upgrading IT services to adapt to changing industry trends.

As investors rotate toward the healthcare industry to hedge against current market volatility, Wall Street analysts expect the share prices of T2 Biosystems, Inc. (TTOO) and OpGen, Inc. (OPGN), which are currently trading below $10, to double soon.

Click here to checkout our Healthcare Sector Report for 2021

T2 Biosystems, Inc. (TTOO)

TTOO is a Lexington, Mass.-based in-vitro diagnostics company. The company uses its T2MR technology, which enables rapid detection of pathogens, biomarkers, and other abnormalities in a variety of unpurified patient sample types. It’s T2SARS-CoV-2 Panel is designed to detect SARS-CoV-2, the virus that is responsible for COVID-19 infections.

On May 6, TTOO announced the modification of the terms of its existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of multiple products that are being funded under the contract. If all options are exercised, the multi-year contract between BARDA and T2 Biosystems would be valued at up to $69.0 million, allowing the company to improve its healthcare outcomes and strengthen its position in the industry.

TTOO’s total revenue increased 173.3% year-over-year to $6.96 million in its fiscal first quarter, ended March 31. Its product revenue stood at $4.65 million, up 345% from the same period last year.

A $25.23 million  consensus revenue estimate for the current year indicates a 39.2% increase year-over-year. The Street expects the company’s EPS to improve 20.5% in the current  year versus  the last year. TTOO’s shares have gained 1.9% over the past five days.

All four Wall Street analysts that rated TTOO have rated it Buy. The $3.13 median price target indicates a potential 195.3% upside from its $1.06 last closing price. The 12-month price targets range from a low of $2.50 to a high of $3.50.

OpGen, Inc. (OPGN)

OPGN is a precision medicine company that develops molecular information products and services. The company utilizes molecular diagnostics and informatics to help combat infectious diseases.

On August 3, OPGN announced that its subsidiary, Curetis GmbH, and its instrument development and engineering partner have successfully achieved key development milestones in its Unyvero A30 RQ platform program. This should allow the company to expand its product portfolio as well as engage in strategic partnering and licensing discussions to leverage and monetize the A30 RQ platform.

OPGN’s total revenue increased 34.5% year-over-year to $0.83 million in its fiscal first quarter, ended March 31. Its product sales increased 67.3% from the year-ago value to $0.61 million.

Analysts expect OPGN’s revenues to increase 84.9% year-over-year to $7.79 million in the current year. The company’s EPS is expected to improve 46.8% in the current  year versus the last year. Shares of OPGN have gained 9.1% over the past five days and 17.7% year-to-date.

The two Wall Street analysts that rated OPGN have rated it Buy. The $5.50 median price target indicates a potential 129.2% upside from its $2.40 last closing price. The 12-month price targets range from a low of $4.00 to a high of $7.00.

Click here to checkout our Healthcare Sector Report for 2021


TTOO shares were trading at $1.21 per share on Wednesday afternoon, up $0.15 (+14.15%). Year-to-date, TTOO has declined -2.42%, versus a 18.38% rise in the benchmark S&P 500 index during the same period.


About the Author: Subhasree Kar


Subhasree’s keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master’s degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
TTOOGet RatingGet RatingGet Rating
OPGNGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Holiday Stock Rally is an “Optical Illusion”

Holiday sessions like this week have a naturally bullish bias for stocks (SPY). That’s because the joy of Thanksgiving typically leaks over to higher stock prices. The risk is giving this upward movement any significance when the long term trajectory is still decidedly bearish. Let’s do a roll call of recent events that continues to point the compass to more downside action ahead along with our game plan to profit as stocks make new lows in the weeks ahead.

:  |  News, Ratings, and Charts

3 Upgraded Stocks to Check out This Week

Equities have jumped recently on hopes that the Fed will soon begin to slow its rate hikes as inflation shows signs of easing. However, the year-end market rally is expected to meet the recession reality in 2023. Amid an uncertain market outlook, investors should consider buying fundamentally strong stocks Cisco (CSCO), Bridgestone (BRDCY), and KT Corporation (KT), which have been recently upgraded in our proprietary rating system. Keep reading…

:  |  News, Ratings, and Charts

The Best Software Stock to Buy in November and the Worst

With inflation showing signs of cooling, the Fed is expected to slow down its rate hike aggression in the coming months. This might bode well for the tech and software industry. Moreover, amid rapid digitization, the growth prospects of the software industry should remain solid. Thus, quality software stock Commvault Systems (CVLT) might be an ideal buy for November. However, we believe fundamentally weak Robinhood (HOOD) might be best avoided. Keep reading…

:  |  News, Ratings, and Charts

2 Stocks to Sell Before They Bleed More Cash

The benchmark indexes witnessed a freefall this year amid deteriorating investors’ sentiments. Therefore, amid widespread recession concerns and a poor global economic growth outlook, we advise our investors to avoid already hard-hit and fundamentally weak stocks Snap (SNAP) and Pineapple Energy (PEGY). Read more...

:  |  News, Ratings, and Charts

The Best Software Stock to Buy in November and the Worst

With inflation showing signs of cooling, the Fed is expected to slow down its rate hike aggression in the coming months. This might bode well for the tech and software industry. Moreover, amid rapid digitization, the growth prospects of the software industry should remain solid. Thus, quality software stock Commvault Systems (CVLT) might be an ideal buy for November. However, we believe fundamentally weak Robinhood (HOOD) might be best avoided. Keep reading…

Read More Stories

More T2 Biosystems, Inc. (TTOO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TTOO News